Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study.

Prior oral anticoagulation experience influences bleeding risk, but abelacimab reduces bleeding consistently across atrial fibrillation patients, with greater benefit in OAC-naïve individuals.

• Why it matters: Understanding how previous anticoagulation impacts bleeding risk helps optimize treatment strategies for atrial fibrillation patients, especially when choosing new therapies.
• What they did: The study analyzed data from AZALEA-TIMI 71, focusing on 1,200 patients, to assess bleeding outcomes with abelacimab, a factor XI inhibitor, in those with or without prior OAC use.
• The result: Abelacimab significantly lowered bleeding risk regardless of prior OAC, offering the greatest absolute benefit for patients new to anticoagulation, supporting its potential as a safe alternative.